MedPath

Efficacy of platelet rich fibrin (PRF)for the prevention and the treatment of Medication Related Osteonecrosis of the Jaw(MRONJ)

Not Applicable
Conditions
Medication Related Osteonecrosis of the Jaw
Registration Number
JPRN-UMIN000022479
Lead Sponsor
Matsumoto Dental University
Brief Summary

So far, two patients were enrolled in this clinical study and PRF was administered sumultaneously at the time of necrotic bone removal (preventive purpose). In both patients, the region was healed and no recurrence was observed during the observation period.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with serious endocrine metabolic diseases and autoimmune diseases. Patients with sepsis or potential sepsis. Patients with hematologic diseases, blood disorders, blood coagulation disorders and liver diseases and having difficulty of transplantation. Positive for any of syphilis, HBV antibody, HCV antibody, HIV antibody and HTLV-1 antibody. Patients with transmissible spongiform encephalopathy, potent transmissible spongiform encephalopathy or dementia. Patients with genetic diseases including sclerosing lesion of bone. Any other conditions that the dentists in charge consider inappropriate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath